Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsParkland Community Rylaze Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentParkland Community Health PlanPolicy N/A

    Asparaginase Erwinia (recombinant)-rywn (Rylaze®)

    Customize your policy alerts

    Sign up for all parklandcommunityhealthplan policy alerts

    Know when parklandcommunityhealthplan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy establishes medical-necessity and prior-authorization requirements for Rylaze used to treat acute lymphoblastic leukemia or lymphoblastic lymphoma in Parkland Community Health Plan members. It applies to members enrolled in STAR and CHIP.

    Policy Summary
    PayerParkland Community Health Plan
    PolicyAsparaginase Erwinia (recombinant)-rywn (Rylaze®)
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateSeptember 6, 2024
    Next Review DateDecember 17, 2025
    Key ActionDocument that Rylaze is prescribed by a hematologist-oncologist for a member with ALL or LBL who is at least 1 month old and has developed hypersensitivity to an E. coli-derived asparaginase product or pegaspargase.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    ALL or LBLCovered disease indications
    ≥1 monthMinimum member age
    6 monthsMaximum approval duration
    STAR and CHIPApplicable plan programs

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Hematologist-oncologistRequired prescriber specialty

    Coverage Criteria

    Initial Therapy

    Rylaze is medically necessary for initial therapy when ALL of the following criteria are met:

    ALL of the following

    • Prescribing is limited to a hematologist-oncologist.
    • Member has a diagnosis of acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL).
    • Member is at least 1 month of age.>= 1 month
    • Member has hypersensitivity to an E. coli-derived asparaginase product or pegaspargase (Oncaspar®).
    • No contraindications or boxed warnings are present

      • No history of serious hypersensitivity reactions, including anaphylaxis, to asparaginase (Erwinia) or any component of the formulation.
      • No history of serious pancreatitis, serious thrombosis, or serious hemorrhagic events with prior asparaginase treatment.
      • No severe hepatic impairment.
    • Member will be monitored according to FDA-approved labeling and best practices.

    Continuation Therapy

    Rylaze is medically necessary for continuation therapy when ALL of the following criteria are met:

    ALL of the following

    • All Initial Approval Criteria continue to be met, including the covered diagnosis, age requirement, qualifying hypersensitivity to an E. coli-derived asparaginase product or pegaspargase, absence of contraindications or boxed warnings, hematologist-oncologist prescribing, and monitoring according to FDA-approved labeling and best practices.
    • Member has shown improvement from therapy.
    • Continuation approval is limited to a maximum of 6 months.<= 6 months

    Coverage is excluded when the member has a history of serious hypersensitivity reactions, including anaphylaxis, to asparaginase (Erwinia) or any component of the Rylaze formulation; a history of serious pancreatitis, serious thrombosis, or serious hemorrhagic events with prior asparaginase treatment; or severe hepatic impairment. Rylaze is also restricted to the covered indication and age requirements and must be prescribed by a hematologist-oncologist.

    type

    Initial Rylaze Approval

    Initial Rylaze Approval

    Initial Rylaze therapy is medically necessary when ALL of the following criteria are met:

    Initial Rylaze approval

    • Prescriber: Prescribing is limited to a hematologist-oncologist.
    • Diagnosis: The member has acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL).ALL or LBL
    • Age: The member is at least 1 month old.≥1 month

    Continued Rylaze Therapy

    Continued Rylaze Therapy

    Continued Rylaze therapy is medically necessary when ALL of the following criteria are met:

    Continued Rylaze therapy

    • Initial indications remain met: All indications from the initial approval criteria continue to be met.
    • Clinical response: The member has shown improvement from therapy.
    • Monitoring: The member is monitored according to FDA-approved labeling and best practices.

    Authorization Parameters

    Minimum age
    Minimum member ageAt least 1 month old
    Maximum approval duration
    Maximum approval duration6 months

    Prior Authorization and Documentation

    Prior Authorization

    Initial Authorization Requirements

    Rylaze requires prior authorization and is medically necessary only when prescribed by a hematologist-oncologist for a member with ALL or LBL who is at least 1 month old and has hypersensitivity to an E. coli-derived asparaginase product or pegaspargase (Oncaspar).

    • Document the diagnosis of acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL).
    • Document member age of at least 1 month.
    • Document hypersensitivity to an E. coli-derived asparaginase product or pegaspargase (Oncaspar).
    Prior Authorization

    Continuation Authorization and Duration

    Continued Rylaze coverage requires that all initial-approval indications remain met, the member has shown improvement with therapy, and monitoring is performed according to FDA-approved labeling and best practices. Approval is limited to a maximum of 6 months.

    • Maintain documentation supporting all initial approval criteria.
    • Document clinical improvement from therapy.

    Clinical Background

    Asparaginase Erwinia recombinant-rywn is an asparagine-specific enzyme used in Rylaze for the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL). The policy applies to adults and pediatric patients who are at least 1 month old and who have developed hypersensitivity to an E. coli-derived asparaginase product or pegaspargase.

    Policy Definitions

    Definition
    Asparaginase Erwinia recombinant-rywnAn asparagine-specific enzyme used as the active therapeutic component of Rylaze.
    Definition
    ALLAcute lymphoblastic leukemia.
    Definition
    LBLLymphoblastic lymphoma.
    Policy Summary
    PayerParkland Community Health Plan
    PolicyAsparaginase Erwinia (recombinant)-rywn (Rylaze®)
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateSeptember 6, 2024
    Next Review DateDecember 17, 2025
    Key ActionDocument that Rylaze is prescribed by a hematologist-oncologist for a member with ALL or LBL who is at least 1 month old and has developed hypersensitivity to an E. coli-derived asparaginase product or pegaspargase.
    SourceLink
    On This Page
    Coverage CriteriaInitial Rylaze ApprovalContinued Rylaze TherapyAuthorization ParametersPrior Authorization and DocumentationClinical BackgroundPolicy Definitions
    Hypersensitivity history: The member has developed hypersensitivity to an E. coli-derived asparaginase product or pegaspargase (Oncaspar).
  1. No contraindications or boxed warnings

    • Hypersensitivity exclusion: No history of serious hypersensitivity reactions, including anaphylaxis, to Erwinia asparaginase or any component of the formulation.
    • Prior serious toxicity exclusion: No history of serious pancreatitis, serious thrombosis, or serious hemorrhagic events with prior asparaginase treatment.
    • Hepatic function exclusion: No severe hepatic impairment.
  2. Monitoring: The member is monitored according to FDA-approved labeling and best practices.
  3. Maximum approval duration: 6 months.
  4. Documentation Required

    Monitoring Documentation

    The member must be monitored according to FDA-approved labeling and best practices during both initial and continued therapy. Include monitoring documentation with the authorization request and continuation request.

    • Initial therapy: document monitoring consistent with FDA-approved labeling and best practices.
    • Continued therapy: document ongoing monitoring consistent with FDA-approved labeling and best practices.
    Denial Risk

    Failure to Meet Initial Approval Criteria

    Initial therapy will be denied when any required approval criterion is not met, including the prescriber specialty, covered diagnosis, minimum age, or qualifying hypersensitivity documentation.

    • Prescriber is not a hematologist-oncologist.
    • Diagnosis is not ALL or LBL.
    • Member is younger than 1 month.
    • Hypersensitivity to an E. coli-derived asparaginase product or pegaspargase is not documented.
    • Required initial-therapy documentation or monitoring is absent.
    Denial Risk

    Contraindications and Boxed Warnings

    Rylaze will be denied when a listed contraindication or boxed-warning risk is present, including serious hypersensitivity to Erwinia asparaginase or a formulation component, serious prior asparaginase-related pancreatitis, thrombosis, or hemorrhage, or severe hepatic impairment.

    • History of serious hypersensitivity reactions, including anaphylaxis, to asparaginase (Erwinia) or any formulation component.
    • History of serious pancreatitis with prior asparaginase treatment.
    • History of serious thrombosis with prior asparaginase treatment.
    • History of serious hemorrhagic events with prior asparaginase treatment.
    • Severe hepatic impairment.
    Denial Risk

    Failure to Meet Continuation Criteria

    Continued coverage will be denied when the initial indications are no longer met, the member has not shown improvement from therapy, or required ongoing monitoring documentation is unavailable.

    • One or more initial approval criteria are no longer satisfied.
    • No improvement from therapy is documented.
    • Monitoring is not performed or is not documented according to FDA-approved labeling and best practices.